Please assess the completion status of the following clinical trial:

Trial Title: Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years old with previously untreated, histologically confirmed Marginal Zone Lymphoma (non-gastric extranodal MZL, splenic MZL and nodal MZL) or gastric MZL that did not respond to antibiotic therapy given up to 6 months prior to enrollment, but not less than 2 months)~* Measurable and evaluable disease~* All stages are eligible~* Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 (Appendix B)~* Willing and able to provide written informed consent~* Women of childbearing potential must have a negative pregnancy test at study entry and must agree to use effective contraception while on treatment and for 6 months after treatment~* Life expectancy of at least 6 months~Exclusion Criteria:~* Prior chemotherapy, radiation therapy, immunotherapy, systemic corticosteroids, or systemic biologic anticancer therapy before beginning study treatment.~* ≥ 25% lymphoma bone marrow involvement~* Platelet count \< 100,000 cells/mm³~* Neutrophil count \< 1,500 cells/mm³~* Known history of HIV infection~* Pregnant or lactating (pregnancy test is required for all female patients of childbearing potential)~* Woman of childbearing potential or sexually active man unwilling to use adequate contraceptive protection.~* Physical or mental condition that makes patient unable to complete specified follow-up assessments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Zevalin + Rituximab (Type: EXPERIMENTAL): Ibritumomab Tiuxetan (Zevalin) + Rituximab

Based on this trial design, predict the completion outcome and termination type (if applicable).